DLA Piper suggested Brookline Capital Acquisition Corp., a unique reason acquisition organization, in the closing of its business enterprise combination with Apexigen, Inc., a medical-phase biopharmaceutical firm. The put together, publicly traded corporation will run less than the name Apexigen, and its popular stock commenced trading on the Nasdaq Money Industry on August 1, 2022 below the ticker symbol “APGN.”
Apexigen is a medical-phase biopharmaceutical corporation focusing on the discovery and advancement of revolutionary antibody-based mostly therapeutics for the treatment method of cancer with a concentration on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is at this time in Period 2 clinical improvement, and also involves quite a few preclinical stage immuno-oncology courses.
“On behalf of our deal team, it was an honor functioning with Brookline Funds Acquisition and combining our SPAC M&A capabilities with our experience in the healthcare sector to help this transaction and Apexigen’s future progress,” said Jeffrey Selman, chair of DLA Piper’s SPAC Transactional follow and the companion who led the firm’s offer group.
“We are pretty pleased to have labored with the remarkable team at DLA Piper, led by Jeff Selman and James Kelly. Their direction and aim was instrumental in the timely completion of this elaborate transaction, and for that we are grateful,” claimed Samuel Wertheimer, Chairman and CEO of Brookline Money Acquisition Corp.
“Congratulations to Brookline Funds Acquisition and Apexigen on this offer. This is a considerable milestone for Apexigen as it proceeds to unlock progressive solutions in the oncology room, and we’re grateful to be a aspect of it,” said James Kelly, head of DLA Piper’s New York Non-public Equity exercise.
In addition to Selman (San Francisco) and Kelly (New York), the DLA Piper group representing Brookline Money Acquisition incorporated partners Peter Ekberg (Minneapolis), Alan Seem, Carole Bellis (the two in Silicon Valley) and Ilya Bubel (New York), and associates Spencer Hodson (Sacramento), Wei Li (Silicon Valley) and Peter Phillips (New York).
With extra than 1,000 corporate legal professionals globally, DLA Piper assists clients execute elaborate transactions seamlessly although supporting customers across all phases of enhancement. The business has been rated quantity one in world wide M&A quantity for 12 consecutive yrs, in accordance to Mergermarket.
The firm’s Health care sector is composed of a multidisciplinary legal staff with market expertise in health-relevant company and lawful difficulties. The workforce routinely is effective with corporations and economic establishments, non-public investors, private fairness teams, enterprise funds resources, institutional traders and portfolio companies in all sorts of healthcare transactions.